{
    "ticker": "PEPG",
    "name": "PepGen, Inc.",
    "description": "PepGen, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare and debilitating genetic diseases. Founded in 2017 and headquartered in Cambridge, Massachusetts, PepGen leverages its proprietary technology platform, which includes its unique peptide-based delivery system, to enhance the delivery of therapeutics to target tissues. The company's mission is to improve the lives of patients by providing transformative treatments for conditions caused by genetic mutations. PepGen is particularly focused on neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD) and other related disorders. The firm is advancing multiple product candidates through clinical development, including its lead compound, which aims to restore dystrophin expression in muscle cells. With a strong emphasis on research and development, PepGen collaborates with leading academic institutions and industry partners to drive innovation and ensure the efficacy and safety of its therapies. The company\u2019s commitment to patient-centric solutions is evident in its engagement with patient advocacy groups and stakeholders to better understand the needs of the communities it serves. As PepGen continues to grow, it strives to position itself as a leader in the biotechnology sector, dedicated to making a meaningful impact in the lives of those affected by genetic diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2017",
    "website": "https://www.pepgen.com",
    "ceo": "James McGorry",
    "social_media": {
        "twitter": "https://twitter.com/PepGenInc",
        "linkedin": "https://www.linkedin.com/company/pepgen/"
    },
    "investor_relations": "https://www.pepgen.com/investors",
    "key_executives": [
        {
            "name": "James McGorry",
            "position": "CEO"
        },
        {
            "name": "Rachael P. McCulloch",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Lead DMD Compound",
                "Next-Gen Delivery Systems"
            ]
        }
    ],
    "seo": {
        "meta_title": "PepGen, Inc. | Innovative Gene Therapies for Rare Diseases",
        "meta_description": "Explore PepGen, Inc., a biotechnology company dedicated to developing innovative gene therapies for patients with rare genetic diseases. Learn about our mission and pipeline.",
        "keywords": [
            "PepGen",
            "Biotechnology",
            "Gene Therapy",
            "Duchenne Muscular Dystrophy",
            "Genetic Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is PepGen known for?",
            "answer": "PepGen is known for developing innovative therapies for rare genetic diseases, particularly focusing on neuromuscular disorders."
        },
        {
            "question": "Who is the CEO of PepGen?",
            "answer": "James McGorry is the CEO of PepGen, Inc."
        },
        {
            "question": "Where is PepGen headquartered?",
            "answer": "PepGen is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are PepGen's main products?",
            "answer": "PepGen's main products include their lead DMD compound and next-generation delivery systems for gene therapies."
        },
        {
            "question": "When was PepGen founded?",
            "answer": "PepGen was founded in 2017."
        }
    ],
    "competitors": [
        "SRPT",
        "PTCT",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}